Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Macrogenics (MGNX) Gains from Investment Securities (2016 - 2025)

Historic Gains from Investment Securities for Macrogenics (MGNX) over the last 13 years, with Q1 2025 value amounting to $282000.0.

  • Macrogenics' Gains from Investment Securities fell 8820.58% to $282000.0 in Q1 2025 from the same period last year, while for Sep 2025 it was $286000.0, marking a year-over-year decrease of 8842.57%. This contributed to the annual value of $2.5 million for FY2024, which is 68510.64% up from last year.
  • According to the latest figures from Q1 2025, Macrogenics' Gains from Investment Securities is $282000.0, which was down 8820.58% from $4000.0 recorded in Q4 2024.
  • Over the past 5 years, Macrogenics' Gains from Investment Securities peaked at $2.4 million during Q1 2024, and registered a low of -$1.8 million during Q3 2022.
  • Over the past 5 years, Macrogenics' median Gains from Investment Securities value was -$40000.0 (recorded in 2023), while the average stood at -$215250.0.
  • In the last 5 years, Macrogenics' Gains from Investment Securities tumbled by 17966.19% in 2021 and then skyrocketed by 141329.11% in 2024.
  • Macrogenics' Gains from Investment Securities (Quarter) stood at -$433000.0 in 2021, then tumbled by 316.86% to -$1.8 million in 2022, then soared by 95.35% to -$84000.0 in 2023, then surged by 104.76% to $4000.0 in 2024, then skyrocketed by 6950.0% to $282000.0 in 2025.
  • Its last three reported values are $282000.0 in Q1 2025, $4000.0 for Q4 2024, and $74000.0 during Q3 2024.